Predictive factors of activity of anti-programmed death-1/programmed death ligand-1 drugs: immunohistochemistry analysis

Por Chakravarti, Nitin, Prieto, Victor G.
Publicado no Transl Lung Cancer Res (2015)

Integrating the molecular background of targeted therapy and immunotherapy in lung cancer: a way...

Por Pilotto, Sara, Molina-Vila, Miguel Angel, Karachaliou, Niki, Carbognin, Luisa, Viteri, Santiago, González-Cao, Maria, Bria, Emilio, Tortora, Giampaolo, Rosell, Rafael
Publicado no Transl Lung Cancer Res (2015)

Moving towards a customized approach for drug development: lessons from clinical trials with immune checkpoint inhibitors in lung cancer

Por Pilotto, Sara, Carbognin, Luisa, Karachaliou, Niki, Garassino, Marina, Cuppone, Federica, Petraglia, Sandra, Rosell, Rafael, Tortora, Giampaolo, Bria, Emilio
Publicado no Transl Lung Cancer Res (2015)

Programmed cell death protein-1/programmed cell death ligand-1 pathway inhibition and predictive biomarkers: understanding transforming growth factor-beta role

Por Santarpia, Mariacarmela, González-Cao, María, Viteri, Santiago, Karachaliou, Niki, Altavilla, Giuseppe, Rosell, Rafael
Publicado no Transl Lung Cancer Res (2015)

Translational Lung Cancer Research, the 7(th) AME Journal indexed in SCIE

Publicado no Transl Lung Cancer Res (2018)

Adjuvant bevacizumab for resected non-small cell lung cancer: the end of an era?

Por Mountzios, Giannis
Publicado no Transl Lung Cancer Res (2018)

Exogenous glutathione contributes to cisplatin resistance in lung cancer A549 cells

Por Lan, Dong, Wang, Li, He, Rongquan, Ma, Jie, Bin, Yehong, Chi, Xiaojv, Chen, Gang, Cai, Zhengwen
Publicado no Am J Transl Res (2018)

Influence of chemotherapy on EGFR mutation status

Por Luo, Yung-Hung, Chen, Yuh-Min
Publicado no Transl Lung Cancer Res (2013)

Can population data guide surveillance strategies for second primary lung cancers?

Por Arifin, Andrew J., Corkum, Mark T., Louie, Alexander V.
Publicado no Transl Lung Cancer Res (2018)

Can we use interleukin-1β blockade for lung cancer treatment?

Por Gottschlich, Adrian, Endres, Stefan, Kobold, Sebastian
Publicado no Transl Lung Cancer Res (2018)

Stage III non-small cell lung cancer: escalation matters, but how?

Por Hegde, Aparna Madhukeshwar, Walker, Paul Raymond
Publicado no Transl Lung Cancer Res (2018)

Identifying therapeutic vulnerabilities in lung cancer: application of a chemistry-first approach

Por Pine, Sharon R., Ryan, Bríd M.
Publicado no Transl Lung Cancer Res (2018)

Vandetanib in advanced non small cell lung cancer: a promise unfulfilled

Por de Boer, Richard H.
Publicado no Transl Lung Cancer Res (2013)

Quality of life for non-small cell lung cancer patients in the age of immunotherapy

Por Ramirez, Robert A., Lu, Jonathan, Thomas, Katharine E. H.
Publicado no Transl Lung Cancer Res (2018)

Studying the immune landscape in lung cancer models: choosing the right experimental tools

Por Weeden, Clare E., Ah-Cann, Casey, Asselin-Labat, Marie-Liesse
Publicado no Transl Lung Cancer Res (2018)

Gefitinib in non-small-cell lung cancer—an old lesson new re-visited

Por Dempke, Wolfram C. M.
Publicado no Transl Lung Cancer Res (2013)

Histopathologic and molecular approach to staging of multiple lung nodules

Por Schneider, Frank, Dacic, Sanja
Publicado no Transl Lung Cancer Res (2017)

Identifying Metastases-related Information from Pathology Reports of Lung Cancer Patients

Por Soysal, Ergin, Warner, Jeremy L, Denny, Joshua C, Xu, Hua
Publicado no AMIA Jt Summits Transl Sci Proc (2017)

LigaSure meets endobronchial valve in a case of lung cancer with pneumoconiosis

Por Fiorelli, Alfonso, Accardo, Marina, Vicidomini, Giovanni, Santini, Mario
Publicado no Transl Lung Cancer Res (2013)

Adjuvant chemotherapy in patients with completely resected non-small cell lung cancer

Por Pirker, Robert
Publicado no Transl Lung Cancer Res (2014)